| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1377495 | Bioorganic & Medicinal Chemistry Letters | 2006 | 5 Pages |
Abstract
Guided by structure-based drug design, modification of the 1,4-benzodiazepin-2,5-dione lead compound 1 resulted in the discovery of 19, a potent and orally bioavailable antagonist of the HDM2-p53 protein–protein interaction (FP IC50 = 0.7 μM, F ≈ 100%).
Graphical abstractGuided by structure-based drug design, modification of the BDP lead compound 1 resulted in the discovery of 19, a potent and orally bioavailable antagonist of the HDM2-p53 protein–protein interaction (FP IC50 = 0.7 μM, F ≈ 100%).Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Daniel J. Parks, Louis V. LaFrance, Raul R. Calvo, Karen L. Milkiewicz, Juan José Marugán, Pierre Raboisson, Carsten Schubert, Holly K. Koblish, Shuyuan Zhao, Carol F. Franks, Jennifer Lattanze, Theodore E. Carver, Maxwell D. Cummings, Diane Maguire,